Regulatory compliance – Page 51

Inspection responses delayed during FDA/EMA inspection – question-and-answer handling techniques

Managing Delayed Responses during FDA and EMA Inspections: A Playbook for Pharma Professionals Delays in responses during FDA and EMA inspections can create critical bottlenecks for pharmaceutical operations, leading to…

Uncontrolled document revisions during deviation investigation – GDP remediation CAPA

Addressing Uncontrolled Document Revisions During Deviation Investigations: A Complete Guide In the highly regulated pharmaceutical industry, the integrity of documentation is critical, especially during deviation investigations. Uncontrolled document revisions can…

Inspection readiness untested during FDA/EMA inspection – evidence pack inspectors expect

Ensuring Inspection Readiness for FDA and EMA: An Actionable Playbook In the pharmaceutical manufacturing landscape, the complexity of maintaining compliance is ever-increasing. Regulatory inspections by bodies like the FDA and…

GDP errors in batch records during routine operations – evidence pack inspectors expect

Addressing GDP Errors in Batch Records: A Practical Guide for Pharma Professionals In the fast-paced environment of pharmaceutical manufacturing, GDP errors in batch records can result in significant compliance risks…

Team unprepared for interviews during post-inspection response – question-and-answer handling techniques

Strategies for Enhancing Team Readiness for Post-Inspection Interviews Pharmaceutical professionals often find themselves navigating a complex landscape of regulatory inspections, with the stakes higher than ever. A significant concern that…

Data attribution unclear during inspection review – evidence pack inspectors expect

Addressing Unclear Data Attribution During Inspection Reviews: A Practical Guide In the complex landscape of pharmaceutical manufacturing and quality assurance, unclear data attribution can lead to significant challenges during regulatory…

CAPA follow-up weak during FDA/EMA inspection – preventing escalation to warning letter

Improving CAPA Follow-Up During FDA and EMA Inspections to Avoid Warning Letters In the pharmaceutical manufacturing realm, the effectiveness of Corrective and Preventive Actions (CAPA) significantly impacts regulatory outcomes. Weak…

Backdated documentation detected during audit trail review – ALCOA+ gap analysis

Addressing Backdated Documentation Findings: A Comprehensive Playbook for Audits Detecting backdated documentation during an audit trail review can be a significant red flag for pharmaceutical organizations. With regulatory bodies like…

Mock audit findings ignored during remediation tracking – question-and-answer handling techniques

Handling Mock Audit Findings for Effective Remediation Tracking in Pharma In pharmaceutical manufacturing, mock audits serve as crucial tools for identifying compliance deficiencies and ensuring readiness for external inspections. However,…

Illegible entries in controlled records during record archival – evidence pack inspectors expect

Managing Illegible Entries in Controlled Records During Record Archival In pharmaceutical manufacturing and quality control, maintaining clear and legible records is paramount. When illicit entries occur during record archival, they…

Mock audit findings ignored before regulatory inspection – CAPA closure verification

Addressing Ignored Mock Audit Findings Prior to Regulatory Inspections Ignoring mock audit findings can lead to significant complications during actual regulatory inspections. This article aims to equip pharmaceutical professionals with…

GDP errors in batch records during inspection review – inspection citation risk and mitigation

Mitigating GDP Errors in Batch Records During Inspection Review In the highly regulated environment of pharmaceutical manufacturing, maintaining accurate and compliant batch records is paramount. During inspections, any discrepancies in…